[1] Imam Z,Hanna A,Jomaa D,et al.Hypercalcemia of malignancy and acute pancreatitis[J].Pancreas,2021,50(2):206-213.
[2] El-Hajj Fuleihan,G,Clines,G.A,Hu,M.I,et al.Treatment of hypercalcemia of malignancy in adults:an endocrine society clinical practice guideline[J].The Journal of clinical endocrinology and metabolism,2023,108(3):507-528.
[3] Guise T A,Wysolmerski J J.Cancer-associated hypercalcemia[J].The New England journal of medicine,2022,386(15):1443-1451.
[4] Deluque AL,Dimke H,Alexander RT.Biology of calcium homeostasis regulation in intestine and kidney[J].Nephrol Dial Transplant,2025,40(3):435-445.
[5] 邱小亮,姚晨姣.血液肿瘤相关性高钙血症的临床特点及预后因素分析[J].暨南大学学报(自然科学与医学版),2021,42(03):270-277.
[6] 董文静,颜世举,胡佳,等.恶性肿瘤相关性高钙血症药物治疗的研究进展[J].临床内科杂志,2025,42(03):260-262.
[7] Chukir T,Liu Y,Hoffman K,et al.Calcitriol elevation is associated with a higher risk of refractory hypercalcemia of malignancy in solid tumors[J].The Journal of clinical endocrinology and metabolism,2020,105(4):1115-1123.
[8] Barktiewicz P,Kunachowicz D,Filipski M,et al.Hypercalcemia in cancer:causes,effects,and treatment strategies[J].Cells,2024,13(12):1051.
[9] Shah P M,Rasool I,Maguire D.Refractory paraneoplastic hypercalcaemia responding to cinacalcet[J].BMJ case reports,2022,15(11):250576.
[10] Mc Donald D,Drake M T,Crowley R K.Treatment of hypercalcaemia of malignancy in adults[J].Clinical medicine (London,England),2023,23(5):503-507.
[11] Villavicencio Kim J,Saraceni C,Vaziri H.Dysphagia in a cancer patient[J].Dysphagia,2022,37(1):1-3.
[12] Calatroni M,Moroni G,Reggiani F,et al.Renal sarcoidosis[J].Journal of nephrology,2023,36(1):5-15.
[13] 倪奇,陈康.高钙血症的临床诊治和进展:内分泌科视角[J].中国实用内科杂志,2024,44(5):365-372.
[14] 张硕,潘玉真,崔小天.恶性肿瘤相关性高钙血症影响因素与中医证型分析[J].中医药临床杂志,2024,36(3):532-536.
[15] Hu M I.Hypercalcemia of Malignancy[J].Endocrinology and metabolism clinics of north America,2021,50(4):721-728.
[16] Solling AS,Tsourdi E,Harslof T,et al.Denosumab discontinuation[J].Curr Osteoporos Rep,2023,21(1):95-103.
[17] Dickens L T,Derman B,Alexander J T.Endocrine society hypercalcemia of malignancy guidelines[J].JAMA oncology,2023,9(3):430-431.
[18] Wang R,Rajanayagam S,Ngan J,et al.Incidence of post-denosumab rebound hypercalcaemia in bony-metastatic breast cancer[J].Calcified tissue international,2022,111(4):391-395.
[19] Scheen M,Nowak G,Sanchez B,et al.Fine-tuned continuous renal replacement therapy with calcium-free dialysate to manage severe hypercalcemia refractory to medical and intermittent hemodialysis[J].Eur Med Res,2022,27(1):89.
[20] Donato B,Raimundo M,Veiga R.Hypercalcemia and suppressed intact PTH in a hemodialysis patient[J].Kidney360,2022,3(8):1467-1468. |
2025, Vol. 31 
